In the following video, Motley Fool health care analyst Brenton Flynn discusses Bausch & Lomb and the scuttlebutt surrounding a potential acquirer. He talks about Abbott Labs (ABT), Johnson & Johnson (JNJ), Sanofi (SNY), Pfizer (PFE), and Merck (MRK), and just how realistic this purchase would be for each. He also gives his bet on which company, in the end, may be the buyer.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.